RoboSense Launched E1, A High-Performance Flash Solid-State LiDAR and Debuted A Smart Manufacturing System with An Annual Output of A Million Units
8.11.2022 15:28:00 EET | Business Wire | Press release
RoboSense, a world-leading provider of Smart LiDAR Sensor Systems, held a new product launch and Tech Day event. During the conference, RoboSense officially launched RS-LiDAR-E1 (E1), a flash solid-state LiDAR that sees 360° based on its in-house, custom developed chips and flash technology platform. Also debuted was the only China National Accreditation Service (CNAS) recognized on-board LiDAR lab of the industry to date, and held the unveiling ceremony of the smart manufacturing joint venture, Luxsense, jointly with Luxshare-ICT, a domestic leading electronics manufacturer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221108005666/en/
RoboSense Tech Day Launched E1, A High-Performance Flash Solid-State LiDAR and Debuted A Smart Manufacturing System with An Annual Output of A Million Units (Graphic: Business Wire)
RoboSense launched E1, the first automotive-grade flash solid-state LiDAR. It serves as a new product platform featuring area array transceiver technology with application-specific developed chips as the core. E1 is designed for large-scale series production with a simple bill of materials including no moving parts, and excels in all the three aspects of detection performance, cost efficiency and automotive-grade safety and reliability of LiDARs. As a key piece to realizing the core functions of autonomous driving, E1 will assist partners to further bridge the gap in smart driving perception and improve the all-scenario perception capability of automated and autonomous vehicles.
4 core features of E1
- Horizontal FOV of 120°, which ensures 360° coverage area without blind zone using minimum sensors.
- Vertical FOV is designed to be 90°, to allow the perception area to cover both blind zones on the ground and lateral vision.
- Ultra-high frame rates of over 25Hz, capturing target objects’ motion states and predicting their moves faster.
- Detection range of 30m @10%, which enables better perception planning control.
E1 uses RoboSense’s first in-house, custom chips for flash solid-state LiDAR platform and its first 2D electronic scanning technology. With highly integrated chips that incorporate the three core components of transmission, reception, and processing, E1 greatly streamlines the circuit design and production processes, creating the performance and cost advantages necessary for the durability and reliability requirements of blind spot LiDARs in the automotive market.
To ensure product performance and rapidly improve production capacity, RoboSense launched the first and only CNAS certified LiDAR lab to analyze LiDAR and their components and developed a complementary smart manufacturing system to produce this high-tech, precision sensor.
During the event, leaders of RoboSense and Luxshare jointly held the unveiling ceremony of Luxsense. Investment in the first phase of RoboSense smart manufacturing system exceeded 1 billion RMB cumulatively; the plant area exceeds 55,000 square meters including nearly 20 automated production lines built with highly intelligent production software to achieve a top-level production efficiency of “a LiDAR every 12 seconds” and guarantees capacity by connecting our Shenzhen, Dongguan and Guangzhou plants.
Additionally, RoboSense announced a new strategic financing round which attracted top industry investors. In particular, industry investors in this new financing round include car companies with self-owned brands, emerging automakers, top luxury supercar brands, leading commercial vehicle companies, supply chain pioneers and the tier 1 institutions. Greatly empowered by capital investments from the industry, RoboSense gained unprecedented momentum and sustainability.
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. With a complete portfolio of LiDAR sensors, AI perception and IC chipsets, RoboSense transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221108005666/en/
Contact information
Grace Ye
media@robosense.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
